Rapid critical appraisal

Tang et al. (Vaccines 2025) is a timely, wide-ranging narrative review of viral-vector vaccine platforms that accurately synthesizes historical milestones, platform biology, manufacturing bottlenecks, and safety signals (e.g., VITT) while proposing engineering directions (IDLVs, chimeric capsids, insect-specific flaviviruses). Key strengths: breadth, up-to-date references, clear manufacturing/regulatory discussion. Key limits: narrative (non-systematic) design, low reproducibility for any quantitative claim, underweighting of negative/null clinical trials and explicit data on incidence rates across populations. See visual analysis and actionable critiques below.

Primary source: Tang J et al., Vaccines 2025 DOI:10.3390/vaccines13050524

Tang et al., Vaccines 2025 (Review)

Visual, critical review — "Past, Present, and Future of Viral Vector Vaccine Platforms" (Tang et al., Vaccines 2025)

Visual: Platform representation (contextual datapoint)

Visual: High-level pros/cons radar (qualitative)

Concise visual takeaways (clickable deep-dive)

• Platform modularity & plug‑and‑play: review documents rapid reuse of backbones in outbreaks (COVID-19 adenoviral redeployments) but notes supply-chain fragility (filters, single-use plastics) and fill‑finish limits Tang et al., Vaccines 2025 (Manufacturing)
• Safety signals need balanced presentation: Tang et al. correctly highlight VITT/TTS after adenoviral COVID-19 vaccines and discuss putative mechanisms; this is consistent with focused investigations into anti‑PF4 autoantibodies but the review could more rigorously quantify incidence by age/sex/region and discuss case-ascertainment biases in passive surveillance systems VITT mechanistic and epidemiology review
• Pre-existing anti-vector immunity: appropriately stressed (Ad5 example from STEP and hexon-targeting neutralization), and the paper summarizes mitigation (rare serotypes, simian Ad, capsid engineering), but lacks a systematic tabulation of seroprevalence studies across geographies to support general claims Ad5 hexon-targeting neutralization study

What the review does well (evidence-based)

• Comprehensive platform taxonomy and mechanistic immunology overview, including PRR sensing (TLRs, RLRs) and MHC I direct presentation pathways (cites experimental literature).
• Clear exposition of heterologous prime‑boost rationale and real-world relevance (COVID-19 mix-and-match practice).
• Detailed manufacturing and regulatory discussion (cell lines, downstream steps, assays for replication-competent revertants), useful to translational audiences.

Limitations, blindspots, and potential biases

• Narrative (non-systematic) approach: selection bias possible; claims about relative platform advantages are supported by heterogeneous primary studies with varied designs — the review would be strengthened by systematic search and transparent inclusion criteria. Evidence-strength note: narrative synthesis is valuable but lower reproducibility.
• Quantification gaps: rare-event safety signals and seroprevalence claims are not consistently quantified by region, age, or assay—risk of over-generalization from limited datasets.
• Publication/positive-result bias: review frequently cites successful examples (rVSV-ZEBOV, ChAdOx1 rapid deployment) but gives less space to failed or inconclusive vector trials (e.g., Ad5 HIV STEP outcomes beyond noting pre-existing immunity), so readers should interpret efficacy balance cautiously STEP trial (Ad5 HIV)
• Conflict-of-interest depth: authors state no COI, but the review draws heavily on industry- and regulator-influenced literature; a formal tabulation of funder influence on cited pivotal trials would help de-bias interpretation.

Conclusions and practical takeaways (evidence-weighted)

1. Viral vectors remain indispensable for T-cell–oriented vaccines and rapid outbreak responses; rVSV and adenoviral platforms have proven real-world utility but carry platform-specific trade-offs (immunogenicity vs pre-existing immunity and rare safety risks) rVSV‑ZEBOV Guinea ring vaccination
2. Engineering priorities (integrase-defective lentivectors, capsid/chimeric engineering, thermostabilization, lyophilization) are well stated and plausible; success requires head-to-head clinical metrics and manufacturing validation rather than purely preclinical biomarkers.
3. Regulatory and pharmacovigilance harmonization (Brighton, GACVS templates; active surveillance) are necessary; the review notes frameworks but should stress prospective safety‑signal hypothesis testing in platform trials and active case ascertainment to avoid passive-reporting biases Pharmacovigilance for novel vaccines

Actionable recommendations for readers & future authors

• When writing reviews on platforms, prefer a systematic search + PRISMA flow to reduce selection biases and to report explicit inclusion/exclusion rules.
• Provide quantitative tables summarizing seroprevalence of anti-vector antibodies by region and assay, and incidence rates for rare adverse events stratified by demographics, with confidence intervals and data sources.
• Encourage data sharing: registries for manufacturing metrics (YPK yields, downstream recovery rates) and anonymized pharmacovigilance datasets would let third parties validate claims about scalability and safety.

Meta-evidence & citations used in this critique

• Tang et al., Vaccines 2025 (Full review)
• rVSV‑ZEBOV Guinea ring trial
• Ad5 hexon neutralization study
• VITT review
• Pharmacovigilance policy analysis